ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 708,02
-1,99%
Dow Jones
38 647,10
-0,17%
DAX
18 265,68
-2,03%
Brent Oil
82,115
0,17%
Bitcoin
66 776,46
0,03%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Foghorn Therapeutics Inc (FHTX)

  7. Foghorn Therapeutics Inc (FHTX) Actualités

FHTX

Foghorn Therapeutics (FHTX)

Foghorn Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:FHTX
DateHeureSourceTitreSymboleSociété
03/06/202422h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FHTXFoghorn Therapeutics Inc
28/05/202413h00GlobeNewswire Inc.Foghorn Therapeutics to Participate in Upcoming Investor Conferences in JuneNASDAQ:FHTXFoghorn Therapeutics Inc
23/05/202400h21GlobeNewswire Inc.Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance PipelineNASDAQ:FHTXFoghorn Therapeutics Inc
20/05/202422h31Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:FHTXFoghorn Therapeutics Inc
06/05/202413h03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:FHTXFoghorn Therapeutics Inc
06/05/202413h03Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:FHTXFoghorn Therapeutics Inc
07/03/202413h09Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:FHTXFoghorn Therapeutics Inc
25/01/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FHTXFoghorn Therapeutics Inc
28/11/202301h01PR Newswire (US)Flagship Pioneering Marks Official Opening of UK Hub with Event Convening Life Science LeadersNASDAQ:FHTXFoghorn Therapeutics Inc
21/11/202312h00PR Newswire (US)Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of GeneticsNASDAQ:FHTXFoghorn Therapeutics Inc
01/11/202315h30PR Newswire (US)Flagship Pioneering Launches Pioneering IntelligenceNASDAQ:FHTXFoghorn Therapeutics Inc
11/09/202312h30PR Newswire (US)Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development OfficerNASDAQ:FHTXFoghorn Therapeutics Inc
05/09/202314h00GlobeNewswire Inc.Foghorn Therapeutics Announces Participation in Upcoming Investor ConferencesNASDAQ:FHTXFoghorn Therapeutics Inc
31/08/202313h00GlobeNewswire Inc.Foghorn Therapeutics Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed and/or Refractory AMLNASDAQ:FHTXFoghorn Therapeutics Inc
29/08/202315h00PR Newswire (US)Invaio achieves first registration for citrus greening solution featuring Trecise™ technologyNASDAQ:FHTXFoghorn Therapeutics Inc
08/08/202313h00GlobeNewswire Inc.Foghorn Therapeutics Announces Chief Medical Officer SuccessionNASDAQ:FHTXFoghorn Therapeutics Inc
04/08/202313h00GlobeNewswire Inc.Foghorn Therapeutics Provides Second Quarter 2023 Financial and Corporate UpdateNASDAQ:FHTXFoghorn Therapeutics Inc
28/06/202313h06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:FHTXFoghorn Therapeutics Inc
28/06/202313h00GlobeNewswire Inc.Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286 in Metastatic Uveal MelanomaNASDAQ:FHTXFoghorn Therapeutics Inc
05/06/202314h07Dow Jones NewsFoghorn Therapeutics Shares Rally Premarket as FDA Lifts Clinical HoldNASDAQ:FHTXFoghorn Therapeutics Inc
16/05/202312h00PR Newswire (US)Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of BiomimicryNASDAQ:FHTXFoghorn Therapeutics Inc
08/05/202313h07Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:FHTXFoghorn Therapeutics Inc
08/05/202313h06Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:FHTXFoghorn Therapeutics Inc
28/04/202322h07Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:FHTXFoghorn Therapeutics Inc
28/04/202322h01Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:FHTXFoghorn Therapeutics Inc
22/02/202322h23Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:FHTXFoghorn Therapeutics Inc
09/02/202317h02Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:FHTXFoghorn Therapeutics Inc
21/11/202217h35TipRanksMorgan Stanley Keeps Their Hold Rating on Foghorn Therapeutics (FHTX)NASDAQ:FHTXFoghorn Therapeutics Inc
09/11/202212h25TipRanksH.C. Wainwright Sticks to Its Buy Rating for Foghorn Therapeutics (FHTX)NASDAQ:FHTXFoghorn Therapeutics Inc
31/10/202221h02Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:FHTXFoghorn Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:FHTX

Dernières Valeurs Consultées

FTSE
UKX
FTSE 100
EU
DG
Vinci
EU
PX4
SBF 120
EU
BEL20
Bel 20
EU
CAP
Capgemini
NYSE
NKE
Nike
EU
ORA
Orange
NYSE
JPM
JP Morgan Chase
NYSE
KO
Coca Cola
EU
VK
Vallourec
EU
CS
Axa
EU
ACA
Credit Agricole
NASDAQ
AMZN
Amazon.com
EU
LR
Legrand
COIN
BTCUSD
Bitcoin
EU
AI
Air Liquide
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés